May 2025 - Page 2 of 3 - BioMedWire (BMW)

ThursdayMay 22, 2025 10:00 am

Experts Say New Test for Brain Tumors is a Game-Changer

Researchers have developed a novel brain tumor test that surgical experts have dubbed a game changer. This is because the test collapses the needed time to obtain an accurate diagnosis to just hours rather than multiple weeks as has been the case. Surgeons say this new approach can dramatically improve the treatment and care that patients receive after this “ultra-fast” diagnostic tool is used. University of Nottingham scientists, together with a team from the NHS Trust of University of Nottingham Hospitals (NUH) developed this method. Their approach has caused a stir in UK hospitals and many are collecting data on…

WednesdayMay 21, 2025 9:00 am

Adageis Offers Easy-to-Use AI-Driven Solution to Help Healthcare Providers Unlock High-Value Care, Maximize Revenue

Adageis delivers a user-friendly platform that helps providers identify high-value services while improving care quality. The company’s patented ProActive Care Platform leverages AI to shift providers from fee-for-service to value-based care models. The system integrates seamlessly with major EHR platforms to enhance operations without disrupting workflows. Adageis supports over 260,000 patient lives and expects that figure to more than double by the end of Q2 2025. The company is helping providers better understand insurance contract value and advocate for appropriate reimbursement. For healthcare practices navigating the shift toward value-based care, the complexity of insurance contracts, quality metrics, and data reporting…

TuesdayMay 20, 2025 10:00 am

Researchers Discover Potential Missing Connection Between EBV and Multiple Sclerosis

For many years, the scientific community has known that the risk of Multiple Sclerosis is markedly higher among people that have been exposed to the Epstein-Barr virus, the virus which causes infectious mononucleosis (commonly called “mono”). However, it isn’t clear why only a tiny fraction of individuals exposed to “mono” go on to develop MS. Now new research has uncovered a likely explanation why the vast majority of individuals exposed to the mono virus don’t go on to develop multiple sclerosis. According to the study, those who escape MS despite having ever suffered a mono infection have a gene mutation…

TuesdayMay 20, 2025 9:45 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Targets Global Sales Growth with Multilingual Digital Rollout

Medical technology company Intelligent Bio Solutions has launched Arabic, Italian, and Spanish websites to support expansion into key international markets. The move opens digital access to over 1.4 billion people across Latin America, the Middle East, and Southern Europe. The rollout aligns with increased demand for non-invasive workplace drug testing and compliance tools. INBS’s flagship fingerprint sweat-based drug screening system is currently used by over 450 clients in 24 countries. The company plans a U.S. market launch in 2025 as it continues to develop additional biosensor applications. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive…

TuesdayMay 20, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central nervous system disorders. The company’s lead candidate, NRX-100 (preservative free IV ketamine), NDA in process with the FDA, has been granted Fast Track designation by the FDA for acute suicidal depression, and a patent for this novel formulation has been filed with the U.S. Patent and Trademark Office. NRX-101 (oral D-cycloserine/lurasidone), has received FDA Breakthrough Therapy designation, expediting its development. HOPE Therapeutics, NRx’s interventional psychiatry subsidiary, is targeting $100M in forward looking revenue by year-end 2025, through development of a national clinic network treating suicidal depression,…

MondayMay 19, 2025 2:30 pm

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he’s pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell…

MondayMay 19, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results

Q1 milestones are representative of Soligenix’s commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs. The company noted positive interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) treatment. Soligenix announced the release of a publication describing the preclinical efficacy of CiVax(TM), a thermostabilized subunit vaccine against SARS-CoV-2. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases, recently announced its financial results for the first quarter of 2025, alongside a summary of the company’s latest accomplishments (https://ibn.fm/OMQmM). These milestones are representative of Soligenix’s continued…

MondayMay 19, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO

Experienced leadership contributes to key performance indicators. Dr. Eric Poma brings more than 30 years of experience to his new role as CLDI CEO. His expertise will help the company develop and advance proprietary groundbreaking therapies. Effective leadership is a cornerstone of organizational success, particularly in the dynamic and high-stakes realm of biotechnology. Recognizing the pivotal role of seasoned leadership, Calidi Biotherapeutics (NYSE American: CLDI) has announced the appointment of Eric Poma, PhD, as its new Chief Executive Officer and member of the board of directors (https://ibn.fm/qMEu4). This strategic transition underscores Calidi’s commitment to advancing its innovative cancer therapies under experienced guidance. Dr.…

FridayMay 16, 2025 10:00 am

New Multimodal AI System Boosts the Accuracy of Lung Cancer Screening

Early diagnosis of lung cancer is pivotal to effective treatment because this disease is very challenging to treat. Advances in AI are transforming the screening for this disease, improving both efficiency and accuracy. Existing screening methods such as low-dose CT have several challenges. These include high rates of false-positives and a high variability when reporting other incidental but critical information, such as findings on cardiovascular diseases. Furthermore, the shortage of radiologists around the world means that less than 10% of people who need low-dose CT scans can actually undergo them. New research published in the journal Nature Communications shows that…

ThursdayMay 15, 2025 10:00 am

Will Trump’s Executive Order on Drug Prices Yield the Desired Results

While President Trump signed an order aimed at reducing the high cost of prescription drugs in the U.S., it isn’t clear how exactly the price reduction will be achieved and how such reductions could impact the country in the long term. The President said patients in America pay a lot more for prescription drugs than the cost incurred for the same drugs in other countries. He added that he was going to order drug firms to slash their prices within the U.S. There has been a growing concern about the high cost of prescription drugs in America and data exists…